Guildford, UK, 12 August 2005: ReNeuron Group Plc (“ReNeuron” or the “Company”) announces that trading in the Company’s ordinary shares and warrants will commence today at 08:00 on London’s Alternative Investment Market (“AIM”), under the ticker symbols RENE.L’ and RENW.L’ respectively.
Guildford, UK, 5 August 2005: ReNeuron Group plc (“ReNeuron” or the “Company”), the UK-based adult stem cell company, today announces that it has successfully completed its flotation on AIM (“Alternative Investment Market”).
10 million placing to fund first human stem cell trial in major CNS disease
Guildford, Surrey, UK, July 6 2005: ReNeuron, the UK-based adult stem cell research and development company, announced today that it has entered into an agreement with StemCells, Inc. (NASDAQ: STEM), a leading US adult stem cell development company. The agreement gives StemCells exclusive access to ReNeuron’s proprietary c-mycER adult human stem cell immortalisation technology for use in the development of therapies for certain diseases targeted by StemCells, including lysosomal storage diseases, spinal cord injury, cerebral palsy and multiple sclerosis.
ReNeuron, the UK-based stem cell research and development company, has noted the recent publication in Nature Medicine of findings by US researchers indicating that human embryonic stem cell lines (ESCs) have been contaminated by non-human molecules derived from the animal feeder cell layers used to grow the cells.
ReNeuron, the UK-based stem cell research and development company, is pleased to announce that a consortium led by it has been awarded a £2.2 million grant from the UK Department of Trade and Industry (DTI) under its Technology Programme.
ReNeuron, the UK-based stem cell research and development company, is today presenting further pre-clinical efficacy data with its neural (brain) stem cell lines at the Society for Neuroscience 34th Annual Meeting (SfN) in San Diego, USA. Dr Kenny Pollock, ReNeuron’s Head of Stem Cell Biology, will give the platform presentation.
ReNeuron, the UK-based stem cell research and development company, is pleased to give an update on recent progress and future plans regarding its stem cell programmes. The Company is today separately announcing groundbreaking pre-clinical efficacy data with its ReN001 cell therapy programme for stroke. Based on this progress, the Company also announces its intention to seek further funding in order to progress its lead stem cell therapy programmes to the clinic.
ReNeuron, the UK-based stem cell research and development company, is today presenting ground-breaking efficacy data with its lead stem cell line at the American Neurological Association Annual Meeting (ANA) in Toronto, Canada.
Following its recent acquisition by St James MGP Limited, ReNeuron Holdings PLC has now completed its re-registration as a private company under its new name, ReNeuron (UK) Limited. Effective 1 October, Dr Martin Edwards has resigned as Chief Executive Officer and will leave the ReNeuron Board to take up a position at Novo A/S. Also effective from this date, Michael Hunt, currently Chief Financial Officer, is appointed Chief Operating Officer.
Mark Clement, Chief Executive Officer of Merlin Biosciences, and Mark Docherty, Investment Director at Merlin Biosciences, have joined the ReNeuron Board as non-executive Directors. Professor Trevor Jones will continue as non-executive Chairman, his fellow directors now being Mark Clement and Mark Docherty (representing both Merlin and St James’s MGP Limited), together with Michael Hunt and Dr John Sinden (Chief Scientific Officer).
Professor Jones said:
On behalf of the Board, I should like to offer my sincerest thanks to Martin Edwards for his significant contribution to ReNeuron’s success to date, and to wish him well in his next endeavour. I should also like to congratulate Michael Hunt on his appointment as Chief Operating Officer and to welcome Mark Clement and Mark Docherty to the Board.
ReNeuron’s core stem cell technology continues to carry great promise, and I am pleased and excited to remain involved with the Company as it enters its next phase of development.’
Notes to editors
ReNeuron is a UK bio-pharmaceutical company developing proprietary treatments for neurological disorders. Its focus is the development of innovative neural stem cell transplantation technology for the treatment of brain diseases such as Parkinson’s disease, Huntington’s disease and stroke. The Company is also exploiting the use of its stem cell lines as a drug discovery platform through its ReNcell product, which is marketed to pharmaceutical companies and academia for use as a drug discovery tool and for general research. ReNeuron’s stem cells also have the capability to form neural networks suitable for use in biosensors, currently being developed as a potential detection tool to combat bio-terrorism or as a drug-screening tool in the pharmaceutical industry.
Professor Trevor Jones
+ 44 (0)207 930 3477
Michael Hunt ReNeuron (UK) Limited
+44 (0)1483 302560